People on the Move
Avillion
Avillion, a UK company which partners with drugmakers to drive late-stage drug candidates to market, has appointed Jarrod Longcor as Chief Business Officer.
Longcor will take on responsibility for strategic alliances, co-development agreements and financial investments, as well as joining the Executive leadership team.
He brings to Avillion 18 years of pharmaceutical and biotech experience, and was previously the VP of Corporate Development for Rib-X Pharmaceuticals (now Melinta Therapeutics). In this role, he was responsible for several important partnerships, including a major discovery collaboration with Sanofi Aventis valued at over $700m (€550m).
Allison Jeynes-Ellis, CEO of Avillion, welcomed Longcor, saying one of his first priorities will be Avillion’s first collaborative development programme with Pfizer on a Phase III trial of Bosulif in chronic myelogenous leukaemia.
The company was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma.